Ambroxol
Identification
- Name
- Ambroxol
- Accession Number
- DB06742
- Description
Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract which play an important role in the body’s natural defence mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Ambroxol (DB06742)
- Weight
- Average: 378.108
Monoisotopic: 375.978589 - Chemical Formula
- C13H18Br2N2O
- Synonyms
- Ambroxol
- Ambroxolum
- Bisolvon metabolite vIII
- Bromhexine metabolite vIII
- Bromhexine-metabolite vIII
- Cyclohexanol, 4-((2-amino-3,5-dibromobenzyl)amino)- (E)-
- N-(2-Amino-3,4-dibromociclohexil)-trans-4-aminociclohexanol
- N-(2-Amino-3,4-dibromocyclohexyl)-trans-4-aminocyclohexanol
- trans-4-((2-Amino-3,5-dibromobencil)amino)ciclohexanol
- trans-4-((2-Amino-3,5-dibromobenzyl)amine)cyclohexanol
- trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol
- External IDs
- NA-872
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Ambroxol is indicated for secretolytic therapy in bronchoplmonary disease with abnormal mucus secretion and transport. It allows the mucus to be more easily cleared and ease a patient's breathing.
- Associated Therapies
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
Ambroxol is a mucolytic agent. Excessive Nitric oxide (NO) is associated with inflammatory and some other disturbances of airways function. NO enhances the activation of soluble guanylate cyclase and cGMP accumulation. Ambroxol has been shown to inhibit the NO-dependent activation of soluble guanylate cyclase. It is also possible that the inhibition of NO-dependent activation of soluble guanylate cyclase can suppress the excessive mucus secretion, therefore it lowers the phlegm viscosity and improves the mucociliary transport of bronchial secretions.
- Absorption
Rapid and almost complete.
- Volume of distribution
- Not Available
- Protein binding
Approximately 90%
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
7-12 hours
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Ambroxol can be increased when it is combined with Abametapir. Cenobamate The serum concentration of Ambroxol can be decreased when it is combined with Cenobamate. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Ambroxol. Metreleptin The metabolism of Ambroxol can be increased when combined with Metreleptin. Pitolisant The serum concentration of Ambroxol can be decreased when it is combined with Pitolisant. Ritonavir The serum concentration of Ambroxol can be increased when it is combined with Ritonavir. Satralizumab The serum concentration of Ambroxol can be decreased when it is combined with Satralizumab. Tucatinib The metabolism of Tucatinib can be decreased when combined with Ambroxol. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Product Ingredients
Ingredient UNII CAS InChI Key Ambroxol hydrochloride CC995ZMV90 23828-92-4 QNVKOSLOVOTXKF-PFWPSKEQSA-N - International/Other Brands
- Ambrolex (GlaxoSmithKline Inc.) / Ambrox (Square) / Tabcin
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image BOOTS AMBROXOL 30 MG Tablet บริษัท ไบโอแลป จำกัด จำกัด 2000-12-14 Not applicable Thailand 
SHINOXOL TABLET 30 MG Tablet บริษัท วาย.เอส.พี. (ประเทศไทย) จำกัด 2010-08-31 Not applicable Thailand VENTEZE SYRUP Syrup 30 mg/5mL Oral บริษัท ไบโอแลป จำกัด จำกัด 1994-06-06 Not applicable Thailand กาบรอกซอล Tablet บริษัท ห้างขายยาตราเจ็ดดาว จำกัด 2006-05-31 Not applicable Thailand ซีโต้วาน Tablet บริษัท ปัจจุบันโอสถ จำกัด จำกัด 1989-11-09 Not applicable Thailand บรอนคอล Tablet บริษัท สหแพทย์เภสัช จำกัด 2017-03-22 2020-08-24 Thailand ฟาโซลแวน ชนิดเม็ด Tablet 2016-12-26 2019-10-21 Thailand ฟาโซลแวน ไซรัป Syrup 30 mg/5mL Oral บริษัท ห้างขายยาตราเจ็ดดาว จำกัด 2016-12-26 Not applicable Thailand มิวคอน 15 Syrup 15 mg/5mL Oral ห้างหุ้นส่วนจำกัด โรงงานเลิศสิงห์เภสัชกรรม 1998-06-01 Not applicable Thailand มิวคอน ซัยรับ Syrup 30 mg/5mL Oral ห้างหุ้นส่วนจำกัด โรงงานเลิศสิงห์เภสัชกรรม 1993-05-21 Not applicable Thailand
Categories
- ATC Codes
- R03CC63 — Clenbuterol and ambroxol
- R03CC — Selective beta-2-adrenoreceptor agonists
- R03C — ADRENERGICS FOR SYSTEMIC USE
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- Drug Categories
- Adrenergics for Systemic Use
- Amines
- Aniline Compounds
- Cough and Cold Preparations
- Cyclohexanes
- Cyclohexylamines
- Cycloparaffins
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Substrates
- Drugs for Obstructive Airway Diseases
- Expectorants
- Respiratory System Agents
- Selective Beta 2-adrenergic Agonists
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenylmethylamines
- Direct Parent
- Phenylmethylamines
- Alternative Parents
- Benzylamines / 2-bromoanilines / Cyclohexylamines / Cyclohexanols / Bromobenzenes / Aralkylamines / Aryl bromides / Cyclic alcohols and derivatives / Dialkylamines / Primary amines show 3 more
- Substituents
- 2-bromoaniline / Alcohol / Amine / Aniline or substituted anilines / Aralkylamine / Aromatic homomonocyclic compound / Aryl bromide / Aryl halide / Benzylamine / Bromobenzene show 17 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 200168S0CL
- CAS number
- 18683-91-5
- InChI Key
- JBDGDEWWOUBZPM-XYPYZODXSA-N
- InChI
- InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2/t10-,11-
- IUPAC Name
- (1r,4r)-4-{[(2-amino-3,5-dibromophenyl)methyl]amino}cyclohexan-1-ol
- SMILES
- NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1
References
- Synthesis Reference
Kack, J., Koss, F.W., Schraven, E. and Beisenherz, G.; US. Patent 3,536,713; October 27, 1970; assigned to Boehringer lngelheim G.m.b.H.
- General References
- Not Available
- External Links
- PubChem Compound
- 2132
- PubChem Substance
- 347827790
- ChemSpider
- 10276826
- BindingDB
- 50395322
- 625
- ChEBI
- 135590
- ChEMBL
- CHEMBL153479
- ZINC
- ZINC000100070274
- Wikipedia
- Ambroxol
- MSDS
- Download (47.4 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Pharyngitis 4 3 Recruiting Treatment Abnormal Mucus Secretions / Respiratory Tract Diseases 1 2 Completed Basic Science Coughing 1 2 Completed Prevention Allergic Sensitization / Asthma 1 2 Completed Prevention Parkinson's Disease (PD) 1 2 Completed Treatment Hypersensitivity, Food 1 2 Completed Treatment Pain / Pharyngitis 1 2 Not Yet Recruiting Treatment Diffuse Lewy Body Disease 1 2 Not Yet Recruiting Treatment Melanoma 1 2 Not Yet Recruiting Treatment Mucosal Melanoma / Neoadjuvant Treatment 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Syrup Oral 15 mg/5mL Solution Oral Solution 7.5 mg/ml Capsule Oral 75 mg Tablet, soluble Oral 30 mg Solution Oral 7.5 MG/ML Tablet Oral 30 MG Solution Oral 15 MG/ML Syrup Oral 300 mg Solution Oral 0.15 g Syrup Oral 600 mg Solution Oral 0.3 g Solution Oral 15 MG/5ML Capsule, extended release Oral 75 MG Tablet, for solution; tablet, for suspension Oral 30 MG Tablet, effervescent Oral Tablet, effervescent Oral 60 MG Solution Oral 30 MG/5ML Syrup Oral 600 g Tablet, soluble Oral 60 mg Solution Oral; Respiratory (inhalation) 7.5 mg/ml Elixir 30 MG/5ML Syrup Oral 15 mg Syrup Oral 200 mcg Solution Respiratory (inhalation) 7.5 mg/mL Injection, solution Parenteral 15 MG/2ML Tablet Oral 60 MG Granule Oral 30 MG Solution Oral 3 MG/ML Syrup Oral 30 MG/5ML Granule, for suspension Oral 15 MG Spray 15 MG Syrup Oral 0.3 % Tablet, coated Oral 30 MG Tablet, extended release Oral 75 Mg Granule Oral 15 MG/5ML Liquid Oral 3 MG/ML Spray Oral 15 MG/2ML Solution Oral 0.6 g Spray 0.75 % Syrup Oral Granule Oral 30 MG/10ML Syrup Oral 150 mg Granule, for solution Oral 30 mg Granule, for solution Oral 65 mg Granule, for suspension Oral 30 MG Solution Oral 0.75 % Solution Respiratory (inhalation) 15 MG/2ML Spray 15 MG/2ML Suppository Rectal 30 mg Syrup Oral 150 ml Granule Oral 15 MG Tablet 15 MG Tablet 30 MG Syrup Oral 3 MG/ML Syrup Oral 30 MG/10ML Tablet Oral 20 mg Spray Oral 17.86 mg/ml Lozenge Oral 20 MG Liquid Oral 30 mg/5ml Solution / drops; suspension / drops 7.5 MG/ML Solution Intravenous 15 mg/2ml Granule, for solution Oral 15 MG Granule, for solution Oral 60 MG Spray 7.5 MG/ML Suppository Rectal 15 MG Suppository Rectal 60 MG Syrup Oral 200 ML Tablet Oral 15 MG Tablet, coated Oral 60 MG Solution 15 mg/5ml Solution 7.5 mg/1ml Syrup Oral 0.15 g Tablet, film coated Oral 60 MG Granule Oral 2 g Solution Respiratory (inhalation) 15 MG Pastille Oral 15 MG Capsule, extended release Oral Solution Respiratory (inhalation) 0.75 g Solution Oral 30 MG/2ML Tablet, chewable Oral 15 mg Solution Oral 0.005 mg Solution Oral 0.005 mg/5ml Solution / drops; suspension / drops 15 MG/ML Solution Oral 10 MG Solution Oral 15 mg Solution Oral 300 mg Solution Oral 7.5 mg Solution / drops; suspension / drops 15 mg Spray Respiratory (inhalation) 15 MG/2ML Spray Respiratory (inhalation) 30 MG/4ML Syrup Oral 15 mg/mL Solution Intramuscular; Intravenous 2 ml Elixir 15 mg/5ml Lozenge Oral 15 mg Solution Intravenous 1 G/50ML Suspension Oral 300 mg Syrup Oral 250 mg Syrup Oral 0.3 g Syrup Oral 0.6 g Syrup Oral 200 mg Granule, effervescent 30 MG Tablet, effervescent Oral 30 MG Solution Oral 6 MG/ML Spray Oral 2.5 MG Tablet Transmucosal 20 MG Lozenge Oral Tablet Tablet, coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 233-234.5 Kack, J., Koss, F.W., Schraven, E. and Beisenherz, G.; US. Patent 3,536,713; October 27, 1970; assigned to Boehringer lngelheim G.m.b.H. - Predicted Properties
Property Value Source Water Solubility 0.0185 mg/mL ALOGPS logP 3.72 ALOGPS logP 2.65 ChemAxon logS -4.3 ALOGPS pKa (Strongest Acidic) 15.26 ChemAxon pKa (Strongest Basic) 9.01 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 58.28 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 81.94 m3·mol-1 ChemAxon Polarizability 32.8 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Ishiguro N, Senda C, Kishimoto W, Sakai K, Funae Y, Igarashi T: Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes. Xenobiotica. 2000 Jan;30(1):71-80. [PubMed:10659952]
Drug created on September 01, 2010 19:05 / Updated on February 24, 2021 23:07